LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the Jefferies London Healthcare Conference.
Presentation DetailsFormat: Fireside Chat Date: Thursday, November 17, 2022Time: 8:00 a.m.-8:30 a.m. GMT / 3:00 a.m.-3:30 a.m. EST
A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. A replay will be archived for 90 days following the presentation date.
About LAVA TherapeuticsLAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.
CONTACTSInvestor Relations[email protected]
Argot Partners (IR/Media)212-600-1902[email protected]
Source: LAVA Therapeutics N.V.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mueller Water Products Announces Quarterly Dividend
- GRUPO ELEKTRA ANNOUNCES REVENUE OF Ps.44,562 MILLION AND EBITDA OF Ps.6,363 MILLION IN THE FIRST QUARTER OF 2024
- NyquistAI - Advancing Beyond Data to AI Transformation for Life Sciences
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!